InterMune, Inc. has successfully completed large-scale synthesis and delivery to Roche of an API for a hepatitis C virus (HCV) drug candidate ITMN-191, currently in a Phase Ia trial. The milestone triggered a $10 million payment to InterMune as part of the companies’ HCV collaboration. “InterMune has successfully executed key steps in the manufacture of a very sophisticated protease inhibitor molecule and transferred the materials to Roche for future studies,” said Lawrenc...